Search

Displaying all 3 results
DrugBest match

Lebrikizumab

go.drugbank.com/drugs/DB11914
ApprovedInvestigational

Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate. It binds to a different epitope compared tralokinumab. On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolesc...

  1. Indication

    Severe Atopic Dermatitis

    go.drugbank.com/conditions/DBCOND0033062
    Drugs: Abrocitinib · Baricitinib · Betamethasone · Dupilumab · Lebrikizumab · Tacrolimus +1 more
  2. Indication

    Moderate Atopic dermatitis

    go.drugbank.com/conditions/DBCOND0025271
    Drugs: Abrocitinib · Baricitinib · Crisaborole · Desonide · Dupilumab · Fusidic acid +5 more